We offer extracorporeal membrane oxygenation (ECMO) treatments for patients suffering from cardiac and/or pulmonary failure. Based on a holistic understanding of human physiology, we develop extracorporeal life support (ECLS) technologies that can be vital for the survival of critically ill patients.[1-3]

 

We provide solutions combining cardiac and pulmonary support on one technological platform, the Xenios console. It supports gas exchange in the lungs and the cardiovascular system – ECMO thus provides physicians with crucial time for diagnosis and therapy. [1]

Xenios is part of Fresenius Medical Care, the world’s leading provider of products and services for people with renal diseases. As human organs are a mutually linked system, Fresenius Medical Care pursues a multi-organ support approach in Critical Care, drawing on its extensive expertise in extracorporeal blood treatment for acute kidney injury.

We are complementing Fresenius Medical Care’s product portfolio in the field of intensive care and are continuing to shape the future of extracorporeal multi-organ support.

In our daily work, we share a passion for helping people.
For patients. Worldwide. Every day.

 

Visit the Xenios website:
www.xenios-ag.com

 

Reference:

[1] ELSO Guidelines for Cardiopulmonary Extracorporeal Life Support. Extracorporeal Life Support Organization, Version 1.4 August 2017, Ann Arbor, MI, USA

[2] Peek, G. et al. (2009). Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet, 374(9698), 1351–1363

[3] Combes, A. et al. (2018). Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med, 378(21), 1965–1975

 

 

Follow us on Social Media!

  

Products

Events

Events not available

News

ICU Management

Neonatal Extracorporeal Membrane Oxygenation

2023 13 Oct

Xenios sponsored a lunch symposium at the 16th European Conference on Paediatric and Neonatal Ventilation (EPNV) in Montreux (CH) in May 2023. Matteo Di Nardo (Italy) introduced the audience to extracorporeal membrane oxygenation (ECMO) in neonates. Florian Kipfmüller (Germany) presented current knowledge and his experience with ECMO in neonates... Read more

ICU Management

Fresenius Appoints Robert Möller to the Management Board

2023 08 Sep

Robert Möller appointed to the Fresenius Management Board; at the same time, Möller will assume responsibility for hospital group as CEO of Helios Health GmbH  Dr. Francesco De Meo leaves the company  Management Board team continues to drive froward transformation on the way to #FutureFresenius   The Supervisory Board of Fresenius... Read more

ICU Management

Neonatal and Pediatric ECMO with Minilung Petite Kit

2022 02 Nov

Fresenius Medical Care heart & lung launches patient kit, especially for neonatal and pediatric ECMO use Fresenius Medical Care’s heart & lung division Xenios AG introduced the MiniLung petite kit at ESICM LIVES congress this October. This patient kit was developed especially for neonatal and pediatric ECMO.    Fresenius Medical Care’s heart... Read more

ICU Management

Fresenius Medical Care Heart and Lung Enables ECMO Simulation in Virtual Reality

2022 25 Oct

VR app for extracorporeal heart and lung support at ESCIM LIVES 2022 Fresenius Medical Care’s heart & lung division Xenios AG presents its virtual reality application at ESCIM LIVES congress in Paris. Visitors can discover a fictitious ECMO case and interactive hands-on experiences.   Fresenius Medical Care’s heart & lung division Xenios... Read more

ICU Management

Merger: Medos Becomes Fully Integrated Within Xenios AG

2022 01 Sep

Medos Medizintechnik AG was merged into Xenios AG. This streamlines processes within the company and at the same time it grows closer to the parent company Fresenius Medical Care AG & Co. KGaA. Medos Medizintechnik AG (Medos) was founded in 1987 with a focus on cardiopulmonary solutions. Together with Novalung GmbH (Novalung), the company... Read more

ICU Management

Xenios AG Receives Approval in China for ECMO Devices

2021 13 Jul

Xenios A6, a Fresenius Medical Care company, has received approval from the National Medical Products Administration (NMPA) in China for the Xenios console and patient kits for ECMO therapy. In early May, Xenios AG, a Fresenius Medical Care company, received approval for two patient kits in China. It follows NMPA's approval of the Xenios console... Read more

ICU Management

Xenios AG Announces Changes in the Management Board

2021 31 Mar

The Management Board of Xenios AG , the Heart & Lung Business Unit of Fresenius Medical Care, has been restructured. Effective January 31, 2021, the previous Chair of the Executive Board, Dr. Andreas Terpin, has left the company. The new senior trio on the Management Board will continue Fresenius Medical Care's success in the field of extracorporeal... Read more

ICU Management

iLA Membrane Ventilator Enables 36-Year-Old Woman To Survive 143 Days Until Lung Transplantation

2020 31 Aug

Doctors from General University Hospital in Prague saved the life of a 36-year-old woman and mother of a two-year-old child who urgently needed a lung transplant. She survived an incredible 143 days without a full working lung — due to the support of a device called iLA Membrane Ventilator. The iLA Membrane Ventilator is an extracorporeal ventilation... Read more

ICU Management

ECMO becomes crucial therapy in battle against COVID-19 in Europe - Xenios consoles as lifesavers

2020 30 Apr

As the coronavirus spreads and infections with COVID-19 further increase throughout Europe, ECMO therapy turns out to be a necessary option for patients with severe courses.    Xenios AG , a subsidiary of Fresenius Medical Care, provides ECMO consoles that can be used for the treatment of patients who develop severe pneumonia and ARDS with lung... Read more

ICU Management

Novalung System Receives US FDA Clearance

2020 26 Feb

The US FDA (Food and Drug Administration) has granted 510(k) approval to Fresenius Medical Care North America and Xenios, a Fresenius Medical Care company, for long-term use of its Novalung system for patients with acute lung failure or acute cardiopulmonary failure. The FDA announced this on Friday evening. With class II approval, the Novalung... Read more

ICU Management

Merger: Novalung Becomes Fully Integrated within Xenios

2019 02 Sep

Novalung GmbH, which specialises in solutions for respiratory failure, was absorbed into Xenios AG on 30 August 2019. Processes will be streamlined as a result and the company will become more closely aligned with the parent company Fresenius Medical Care. Novalung was established in 2003 and specialises in the treatment of respiratory failure.... Read more

ICU Management

Synchronised Cardiovascular Support Now Ready for the Market

2019 10 Jul

Xenios AG concludes its first clinical study on i-cor Synchronized Cardiac Assist, documenting the safety and feasibility of the synchronized cardiovascular support system. During the “SynCor” trial, a multicentre study treated 47 patients in nine different German clinics using an innovative pulsatile, cardiac-synchronous circulatory support... Read more

ICU Management

Relaunch of the Xenios Website – Now harmonised with that of its parent, Fresenius Medical Care

2019 08 May

The Xenios AG, pioneer in extracorporeal heart and lung support, has restructured its website. Xenios AG has been part of the Fresenius Medical Care Group since 2016 and the new design also serves to bring the company visually in line with the brand image of its parent.   www.xenios-ag.com   With this newly structured website, the... Read more

ICU Management

Six Days Without a Lung – a Look into the Future of Medical Technology

2017 12 Apr

The dramatic story of Canadian Melissa Benoit, who lived for six days without a lung, shows a view of a new chapter in the history of medical technology. The novalung iLA membrane lung, which replaced the functions of the lung, is a product of XENIOS AG. As a strategic partner of XOR Labs in Toronto, both companies wanted to cooperate to revolutionize... Read more

Jobs not available

Catalogue


http://www.xenios-ag.com
[email protected]
Im Zukunftspark, 1
Heilbronn
74076
+49 7131 2706 0

White Papers - Case Studies

Not available

Articles

ICU Management

Neonatal Extracorporeal Membrane Oxygenation

2023 13 Oct

Xenios sponsored a lunch symposium at the 16th European Conference on Paediatric and Neonatal Ventilation (EPNV) in Montreux (CH) in May 2023. Matteo Di Nardo (Italy) introduced the audience to extracorporeal membrane oxygenation (ECMO) in neonates. Florian Kipfmüller (Germany) presented current knowledge and his experience with ECMO in neonates... Read more

Blog

Not available

Content of this tab is based on company profile.

If you are logged in as company user or you are company editor then you can edit company profile here.

http://www.xenios-ag.com
[email protected]
Im Zukunftspark, 1
Heilbronn
74076
+49 7131 2706 0

HEART & LUNG CAMPUS


JOIN – LEARN – CARE

Join the Heart & Lung Campus, our online platform for clinical support, information and education.
Because at Heart & Lung Campus, we know how important it is to have the right knowledge. Our e-learnings provide you with supplementary information on demand, 24 hours a day, 7 days a week – whenever you need it.
True to the motto: “Get ahead with knowledge”!

Virtual ICU

Explore our Virtual ICU with a focus on ECMO treatments and learn more about our product portfolio for extracorporeal heart and lung support!

https://www.heart-and-lung-campus.com/en/tutorial/v-icu/

(Please log in to Heart & Lung Campus first)



Follow us on Social Media!


Find XENIOS On Social Media